ESC 2018 – Xarelto again fails to Command an advantage

Another day, another label-extension trial disappointment for Johnson & Johnson and Bayer’s blood thinner Xarelto. This time the drug fell short in the Commander HF trial, failing to show a benefit over placebo on death and cardiovascular events in patients with worsening heart failure.